Imprint

Published by
Medigene AG
Lochhamer Str. 11
82152 Planegg/Martinsried
T +49-89-200033-0
F +49-89-200033-2920

E-Mail: medigene(at)medigene.com
Web: www.medigene.com

Contact
Public & Investor Relations
Julia Hofmann, Anja Clausnitzer
T +49-89-200033-3301
investor(at)medigene.com

Executive Management Board:
Dr. Frank Mathias (CEO)
Prof. Dolores J. Schendel (CSO)
Peter Llewellyn-Davies (CFO)

HR B 115761
WKN A1X 3W0

Responsible for the Webpage:
Julia Hofmann

Value added tax id: DE167014708
Tax id: 801/22938

Concept and text
Medigene AG, Planegg/Martinsried

Concept, Design und technical realization
Kirchhoff Consult AG, Hamburg

Film
Kirchhoff Consult AG, Hamburg

Photos
Matthias Tunger, München

Translation
arb limited, London
Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Stuttgart

Trademarks

EndoTAG®
is a trademark of Medigene AG

Medigene®
is a trademark of Medigene AG

Medigene ImmunotherapiesTM
is a trademark of Medigene Immunotherapies GmbH

RhuDex®
is a trademark of Medigene AG

TriantaTM
is a trademark of Medigene Immunotherapies GmbH

Trianta ImmunotherapiesTM
is a trademark of Medigene Immunotherapies GmbH

Veregen®
is a trademark of Medigene AG

Eligard®
is a trademark of Tolmar Therapeutics, Inc.

These trademarks may be held or licensed for specific countries.

DISCLAIMER

This annual report contains forward-looking statements that are based on certain assumptions and expectations made by the management of Medigene AG at the time of its publication. These forward-looking statements are therefore subject to unpredictable risks and uncertainties, so there is no guarantee that these assumptions and expectations will turn out to be accurate. Many of those risks and uncertainties are determined by factors that are beyond the control of Medigene AG and cannot be gauged with any certainty at this point in time. This includes future market conditions and economic developments, the behavior of other market participants, the achievement of targeted synergy effects as well as legal and political decisions. Medigene AG cannot preclude that actual results may differ substantially from those expectations expressed in or implied by the forward-looking statements. Medigene AG does not intend or assume any obligation to update any forward-looking statements to reflect events or circumstances after the date of this annual report.

The English version of the annual report is a translation of the original German version; in the event of variances, the German version shall take precedence over the English translation.

PRIVACY INFORMATION

This website uses Piwik, a web analytics open-source software. Piwik uses “cookies”, which are text files placed on your computer, to help the website analyze how users use the site.

The information generated by the cookie about your use of the website (including your IP address anonymized prior to its storage) will be stored on the server of the service provider in Germany. You may refuse the use of cookies by selecting the appropriate settings on your browser, however please note that if you do this you may not be able to use the full functionality of this website.

Top